Kiniksa Pharmaceuticals (KNSA) AI Stock Analysis

• Market Cap: $3.00B
• Dividend Yield: N/A
• Average Volume (3M): 444.70K
• Price to Earnings (P/E): 84.6
• Beta (1Y): 0.57
• Revenue Growth: 55.68%
• EPS Growth: N/A
• Country: US
• Employees: 315
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.23
• Shares Outstanding: 45,161,020
• 10 Day Avg. Volume: 562,729
• 30 Day Avg. Volume: 444,702
• PEG Ratio: 0.08
• Price to Book (P/B): 3.22
• Price to Sales (P/S): 3.34
• P/FCF Ratio: 55.59
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: 4.62
• Enterprise Value/Gross Profit: 8.76
• Enterprise Value/Ebitda: 61.32
• 1Y Price Target: $53.83
• Price Target Upside: 36.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): 1.62
• Revenue Forecast (FY): $900.73M

• Rating: 70 Outperform
• Price Target: $42.00 ▲(6.17% Upside)

The score is supported primarily by strong financial progress and cash generation, plus an upbeat earnings call with raised ARCALYST guidance and improved profitability. Offsetting factors are weak near-term technical momentum and a demanding valuation (high P/E), with execution risks highlighted by rising operating expenses and still-low penetration.

Positive Factors

Revenue Growth

The significant year-over-year revenue growth for ARCALYST demonstrates strong product demand and market acceptance, which is crucial for sustaining long-term financial health and supporting further investment in product development.

Orphan Drug Designation

Receiving Orphan Drug Designation for KPL-387 can provide market exclusivity and regulatory support, enhancing Kiniksa's competitive position in treating pericarditis and potentially driving future revenue growth.

Strong Financial Position

The shift from a net loss to a net income reflects improved profitability and financial management, providing a solid foundation for future growth initiatives and operational stability.

Negative Factors

Limited Market Penetration

Limited market penetration for ARCALYST indicates challenges in expanding its market share, which could hinder revenue potential and necessitate increased marketing and sales efforts.

Decreased Gross Profit Margin

A significant drop in gross profit margin suggests increased costs or pricing pressures, which could impact profitability if not addressed through cost management or pricing strategies.

Rising Operating Expenses

The increase in operating expenses may strain profitability and cash flow, requiring careful management to ensure sustainable growth and financial health.

Kiniksa Pharmaceuticals Business Overview & Revenue Model

Company Description

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

How the Company Makes Money

Kiniksa Pharmaceuticals generates revenue primarily through the commercialization of its therapeutic products, including etokimab, once they receive market approval. The company also explores partnerships and collaborations with larger pharmaceutical firms to co-develop or market their therapies, which can provide upfront payments, milestone payments, and royalties on sales. Additionally, Kiniksa may receive funding through grants or investments aimed at supporting research and development efforts. The success of its revenue model heavily relies on the efficacy and market acceptance of its product candidates, as well as the strategic alliances it forms within the industry.

Kiniksa Pharmaceuticals Financial Statement Overview

Summary

Kiniksa Pharmaceuticals exhibits strong revenue growth and improved profitability, with a significant improvement in net profit margin. The balance sheet shows financial stability with low leverage, although past negative equity is a concern. The cash flow position is robust, supporting operational and strategic initiatives.

Income Statement

Kiniksa Pharmaceuticals has shown a strong revenue growth rate of 12.97% TTM, indicating a positive trajectory. The gross profit margin has decreased from 85.61% in 2024 to 30.90% TTM, which may suggest increased costs or pricing pressures. The net profit margin improved significantly from -10.21% in 2024 to 6.01% TTM, reflecting better cost management or increased efficiency. However, the EBIT and EBITDA margins remain relatively low, indicating room for improvement in operational efficiency.

Balance Sheet

The company's debt-to-equity ratio is low at 0.018 TTM, suggesting conservative leverage and financial stability. The return on equity has improved to 13.99% TTM from negative values in previous years, indicating better profitability. The equity ratio stands at 75.17% TTM, reflecting a strong equity base relative to total assets. However, the company has experienced negative equity in the past, which could pose a risk if financial conditions worsen.

Cash Flow

Kiniksa Pharmaceuticals has demonstrated a robust free cash flow growth rate of 53.00% TTM, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 0.83 TTM, showing a healthy conversion of income to cash. The free cash flow to net income ratio is nearly 1, suggesting efficient cash management. These metrics highlight the company's strong cash flow position, which is crucial for sustaining operations and funding growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	597.97M	423.24M	270.26M	220.18M	38.54M	0.00
Gross Profit	315.52M	362.33M	213.74M	197.28M	29.44M	-3.81M
EBITDA	45.10M	-43.92M	-22.86M	12.18M	-154.28M	-152.42M
Net Income	35.92M	-43.19M	14.08M	183.36M	-157.92M	-161.38M
Balance Sheet
Total Assets	712.33M	580.55M	526.32M	459.67M	232.80M	349.46M
Cash, Cash Equivalents and Short-Term Investments	352.10M	243.63M	206.37M	190.61M	182.20M	323.48M
Total Debt	9.72M	9.86M	12.26M	5.92M	6.05M	6.99M
Total Liabilities	176.95M	142.12M	87.48M	63.52M	47.76M	37.53M
Stockholders Equity	535.38M	438.44M	438.84M	396.15M	185.04M	311.94M
Cash Flow
Free Cash Flow	101.73M	25.41M	13.17M	5.70M	-146.71M	-136.81M
Operating Cash Flow	102.86M	25.69M	13.30M	5.81M	-126.30M	-136.53M
Investing Cash Flow	-52.89M	37.67M	-29.56M	-8.08M	128.63M	-23.44M
Financing Cash Flow	27.51M	12.27M	1.50M	2.52M	5.88M	227.09M

Kiniksa Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 39.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KNSA, the sentiment is Negative. The current price of 39.56 is below the 20-day moving average (MA) of 41.51, below the 50-day MA of 41.14, and above the 200-day MA of 33.17, indicating a neutral trend. The MACD of -0.44 indicates Positive momentum. The RSI at 36.40 is Neutral, neither overbought nor oversold. The STOCH value of 18.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KNSA.

Kiniksa Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	81 Outperform	$2.08B	11.47	25.93%	―	21.13%	50.86%
KNSA	70 Outperform	$3.00B	84.57	7.39%	―	55.68%	―
CGON	57 Neutral	$4.48B	-26.75	-24.74%	―	217.84%	-85.53%
IRON	55 Neutral	$2.91B	-13.26	-34.78%	―	―	-34.96%
BEAM	53 Neutral	$3.59B	-7.23	-47.19%	―	-84.07%	-157.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CNTA	48 Neutral	$2.97B	-12.31	-60.45%	―	117.83%	-18.91%

Kiniksa Pharmaceuticals Corporate Events

Kiniksa Pharmaceuticals Reshapes Leadership With New COO, CSO

On January 10, 2026, Kiniksa Pharmaceuticals appointed Ross Moat as Chief Operating Officer and principal operating officer, formalizing his leadership over commercial operations and expanding his remit to broader functional operations without changing his existing compensation. On the same date, the company named Eben Tessari Chief Strategy Officer, maintaining his oversight of strategic, business development and technical operations while adding responsibility for artificial intelligence initiatives, signaling an operational reorganization aimed at strengthening commercial execution and technology-driven strategy without immediate financial impact on executive pay.

The most recent analyst rating on (KNSA) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Kiniksa Pharmaceuticals stock, see the KNSA Stock Forecast page.